Immune checkpoint blockade (ICB) therapy against negative regulators of the immune system, e.g., CTLA-4, PD-1, or PD-L1, has shown clinical benefits leading to their approval as anticancer drugs in several adult cancer types (4). The gene discussed is CD274; the disease is cancer.